Reditus ‘on the front lines in the fight against cancer

Reditus Laboratories is excited to bring on our first biomarker as we move to the forefront of malignancy and precision pathology. The test will determine whether patients with certain cancers are good candidates for a specific cancer treatment and soon will be available at Reditus.

Reditus Data Confirm Omicron Quickly Became Dominant Variant

Reditus Laboratories’ data have confirmed what some people already suspected — that the omicron variant quickly became the predominant COVID-19 variant in Illinois.

Sick with COVID? Pekin testing lab says 98% of recent samples were omicron variant

PEORIA – Reditus Laboratories in Pekin has provided further proof that the omicron variant is causing most of the COVID-19 infections in Illinois. Of 90 specimens collected Jan. 11-12 and …


Histopathology lab adapts its molecular capabilities to handle ever-greater numbers of SARS-CoV-2 tests By Robert Michel| From The Dark Report Volume XXVIII No. 3 – March 1, 2021 Issue CEO SUMMARY: Last spring, a histopathology lab in Illinois began running molecular COVID-19 tests and decided the clinical side of the lab would focus exclusively on PCR testing […]